CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - HAEI.ORG - A La Une - 03/Sep 17:29
KalVista announces FDA acceptance of NDA for sebetralstat for oral on-demand treatment of HAE
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in [...]
Articles similaires
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
drugs.com - 03/Sep 01:09
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
zacks.com - 05/Sep 15:35
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.
BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium
haei.org - 06/Sep 18:48
BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium BioCryst Pharmaceuticals today announced the presentation of six...
Pharvaris provides business update and expands development program for deucrictibant
haei.org - 05/Sep 18:44
Pharvaris provides business update and expands development program for deucrictibant Pharvaris today announced: The planned initiation of CHAPTER-3,...
KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024
haei.org - 06/Sep 18:54
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024
haei.org - 05/Sep 18:45
Pharvaris presents deucrictibant long-term extension data for both the prophylactic and on-demand treatment of HAE at the Bradykinin Symposium 2024...
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
zacks.com - 11/Sep 16:04
Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.
Les derniers communiqués
-
Aucun élément